Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures
Epilepsia · 2025
DOI: 10.1111/epi.18460 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, 2025. Verfasst von Wesley T Kerr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pyridones, Anticonvulsants, Epilepsies, Partial, Seizures. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Pittsburgh Medical Center, American Brain Foundation, Eisai.
Abstract (Originalsprache)
Objective
In traditionally designed randomized clinical trials of antiseizure medications, participants take a blinded treatment for a prespecified number of weeks, irrespective of continued seizures. The alternative design time to prerandomization monthly seizure count (T‐PSC) allows participants to end the blinded treatment after an individually prespecified number of seizures, which shortens exposure to placebo and ineffective treatment. Previous reanalyses have shown that T‐PSC replicated the efficacy conclusions of trials; therefore, we evaluated whether T‐PSC also could replicate tolerability and safety conclusions.
Methods
We retrospectively applied the T‐PSC design to analyze treatment‐emergent adverse events (TEAEs) from three blinded, placebo‐controlled trials of perampanel for focal onset seizures (NCT00699972, NCT00699582, NCT00700310). We evaluated the incidences of TEAEs, treatment‐related TEAEs, serious TEAEs, and TEAEs that prompted medication adjustment compared to those observed during the full‐length trial.
Results
Of the 1480 participants in the three trials, 1093 experienced any TEAE, of whom 1006 (92%) had onset prior to T‐PSC. When evaluating the differences in each type of TEAE for each dose of perampanel from placebo within each trial, there was no consistent pattern of under‐ or overestimation. Across the three studies, 23 of 79 (29%) serious TEAEs, most requiring hospitalization, occurred after T‐PSC. Significance Almost all TEAEs occurred before T‐PSC. Similar conclusions regarding the tolerability and safety of perampanel would have been reached if the T‐PSC design had been used. This suggests that the T‐PSC design may potentially benefit participants by allowing earlier change from an ineffective treatment to an alternate treatment, which could reduce the risk of serious consequences of ineffective treatment, such as hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Formerly Eisai, Nutley, New Jersey, USA.
- Neurelis, San Diego, California, USA.
- Eisai, Nutley, New Jersey, USA.
- Eisai Europe, Hatfield, Hertfordshire, UK.
ORCID-Profile: Wesley T Kerr, Jacqueline A French
Förderung
- University of Pittsburgh Medical Center
- American Brain Foundation
- Eisai
- NINDS NIH HHS
- the Competitive Medical Research Fund of the University of Pittsburgh Medical Center Health System
- American Academy of Neurology
- the Epilepsy Study Consortium
- Epilepsy Foundation
Zitieren
APA
Kerr, W. T., Ngo, L. Y., Zhu, L., Patten, A., Cheng, J. Y., Biju, L., & French, J. A. (2025). Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures. Epilepsia. https://doi.org/10.1111/epi.18460
Vancouver
Kerr WT, Ngo LY, Zhu L, Patten A, Cheng JY, Biju L, et al. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures. Epilepsia. 2025. doi:10.1111/epi.18460
BibTeX
@article{Kerr2025,
author = {Kerr, Wesley T and Ngo, Leock Y and Zhu, Liang and Patten, Anna and Cheng, Jocelyn Y and Biju, Lavanya and French, Jacqueline A},
title = {Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures},
journal = {Epilepsia},
year = {2025},
doi = {10.1111/epi.18460}
}
EUVIMED